TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05578885

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bier block
Description: patients in group a (n = 25) received 2% lidocaine3 mg/kg (maximum, 200 mg) for IVRA and 2 mL NaCl 0.9% IV , patients in group b (n = 25) received 2% lidocaine 3 mg/kg (maximum, 200 mg) plus 8 mg dexamethasone for IVRA and 2 mL NaCl 0.9% IV , and those in group c (n = 25) received 2% lidocaine 3 mg/kg (maximum, 200 mg) plus fentanyl IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bier block
Description: patients in group a (n = 25) received 2% lidocaine3 mg/kg (maximum, 200 mg) for IVRA and 2 mL NaCl 0.9% IV , patients in group b (n = 25) received 2% lidocaine 3 mg/kg (maximum, 200 mg) plus 8 mg dexamethasone for IVRA and 2 mL NaCl 0.9% IV , and those in group c (n = 25) received 2% lidocaine 3 mg/kg (maximum, 200 mg) plus fentanyl IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bier block
Description: patients in group a (n = 25) received 2% lidocaine3 mg/kg (maximum, 200 mg) for IVRA and 2 mL NaCl 0.9% IV , patients in group b (n = 25) received 2% lidocaine 3 mg/kg (maximum, 200 mg) plus 8 mg dexamethasone for IVRA and 2 mL NaCl 0.9% IV , and those in group c (n = 25) received 2% lidocaine 3 mg/kg (maximum, 200 mg) plus fentanyl IV
Study: NCT05308953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVG-291
Description: NVG-291 is a drug injected under the skin (subcutaneous).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVG-291
Description: NVG-291 is a drug injected under the skin (subcutaneous).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVG-291
Description: NVG-291 is a drug injected under the skin (subcutaneous).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Salt water is being used as a placebo and will be injected under the skin (subcutaneous).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Salt water is being used as a placebo and will be injected under the skin (subcutaneous).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Salt water is being used as a placebo and will be injected under the skin (subcutaneous).
Study: NCT06151262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib+mFOLFIRINOX
Description: This was a single-arm, exploratory study of the combination of Trilaciclib and mFOLFIRINOX in patients with advanced pancreatic cancer receiving first-line therapy. Observed the incidence of chemotherapy-induced myelosuppression, and imaging was performed every four cycles to assess tumor response.
Study: NCT06024304

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synthes TFNA
Description: Surgical fixation with single-screw device Synthes TFNA; Pelvic fractures will be repaired utilizing single-screw device Synthes TFNA.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trigen InterTAN
Description: Surgical fixation with Smith and Nephew Trigen InterTAN cephalomedullary long nail; Pelvic fractures will be repaired utilizing Smith and Nephew Trigen InterTAN.
Study: NCT06055296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMPRENDO Peer Navigation Intervention
Description: Parents randomized to the intervention, COMPRENDO, will receive culture, language, and health literacy-concordant pre-accrual, accrual, and post-accrual activities in person led by a peer navigator for up to 4 weeks. Visit 1 (V1) will provide anticipatory guidance and education on a) general concepts of pediatric cancer research (standard of care, clinical trials, randomization); b) informed consent/assent, research affiliations (e.g., Children's Oncology Group); c) clinical trial types (therapeutic, non-therapeutic); d) voluntariness; and e) frequently asked questions, resources. Navigators will follow a script supported by culture, language and health-literacy concordant handouts and graphic materials, decision aids, and short video-clips. Navigators also provide support with decision-making and answer parents' questions. Three follow-up peer navigator visits (V2, V3, V4) over 4 weeks are tailored to the parents' needs.
Study: NCT04825457

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anchoring-tip vs. Conventional
Description: Anchoring-tip: the snare tip was projected from the sheath by 1-2 mm length. Consequently, a small mucosal incision was made at proximal side of lesion. Then the snare was deployed progressively and adjusted around the lesion trying to obtain free margins. At the final step of both conventional and Tip-in EMR, the lesion was resected.~Conventional: After injection of normal saline solution mix, snaring was tried for polyp resection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anchoring-tip vs. Conventional
Description: Anchoring-tip: the snare tip was projected from the sheath by 1-2 mm length. Consequently, a small mucosal incision was made at proximal side of lesion. Then the snare was deployed progressively and adjusted around the lesion trying to obtain free margins. At the final step of both conventional and Tip-in EMR, the lesion was resected.~Conventional: After injection of normal saline solution mix, snaring was tried for polyp resection.
Study: NCT05183997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: drug will be add to prolong the effect of regional block
Study: NCT06286592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ultra-brief mindfulness intervention video
Description: Details of the specific intervention will be selected in collaboration with the Community Advisory Board.~Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board.
Study: NCT06315608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG-001
Description: MRG-001 is a clear liquid solution for subcutaneous injection
Study: NCT06512389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral solution
Description: 300 mg taken morning and evening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral solution
Description: 300 mg taken morning and evening
Study: NCT05331846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the smell of breast milk
Description: Smell of breast milk during endotracheal aspiration will reduce pain and stress
Study: NCT05085197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1005 injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1005 injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1005 injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1005 injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection
Study: NCT03876873

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head Rotation During Face Mask Ventilation
Description: Participants will receive face mask ventilation in either a neutral head position (practice standard position) or a head rotation position (45 degree angle).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head Rotation During Face Mask Ventilation
Description: Participants will receive face mask ventilation in either a neutral head position (practice standard position) or a head rotation position (45 degree angle).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medline Top Valve Anesthesia Mask
Description: Face mask used per standard of care to provide oxygen to subjects before surgical procedures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medline Top Valve Anesthesia Mask
Description: Face mask used per standard of care to provide oxygen to subjects before surgical procedures.
Study: NCT04900428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-DROPS
Description: COVI-DROPS is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent solution
Study: NCT04634344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD2269
Description: A single dose of DZD2269 starting at 5 mg will be given on Cycle 0 and then followed by a wash-out period. Multiple doses of DZD2269 at the same dose level will be given once daily after the wash-out period.
Study: NCT06150586

Intervention type: OTHER
Intervention: Skin Conductance (SC) Measurement
Description: SC will be measured using a specific monitor and three self-adhesive electrodes on one foot of the infant (one plantar and two on the ankles). Peaks per second (the rate of firing in the sympathetic nerves), average amplitude (mean peaks) and area under curve (forcefulness of sympathetic nerve firing) will be automatically analyzed. Corresponding data will be transferred to a separate tablet computer via bluetooth.

Intervention type: OTHER
Intervention: Video Recording
Description: The video recording for later N-PASS assessment will be done by a camera fixed above the incubator / resuscitation unit, not interfering with the LISA procedure. The video will show the full body of the newborn as well as the hands / forearms of the treating clinical team with the awareness and oral consent of the treating team.
Study: NCT06116448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fidelity simulation
Description: The high-fidelity simulation involved a student and a computer-based mannikin. Prior to the start of the scenario, a pre-briefing session was provided. The scenario was executed with the help of the researcher from the control room. The student's performance during the simulation was recorded with video. Each simulation lasted around 30 minutes. Following the simulation, a debriefing session was held with the student, and feedback was provided. Scales were used to assess the implementation of the practices.
Study: NCT01606358

Intervention type: DRUG
Intervention: Carboplatin and / or taxol chemotherapy
Description: Patient with proven epithelial ovarian cancer and receiving carboplatin and / or taxol chemotherapy (usual care).
Study: NCT06116448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hybrid simulation
Description: The hybrid simulation involved a student and a standardized patient. The patient wore a wearable breast model and held a model baby. Prior to the start of the scenario, a pre-briefing session was provided. The student's performance during the simulation was recorded with video. Each simulation lasted around 30 minutes. Following the simulation, a debriefing session was held with the student, and feedback was provided. Scales were used to assess the implementation of the practices.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telesimulation
Description: The telesimulation involved a student and a standardized patient. The patient wore a wearable breast model and held a model baby. Students and patients communicated via video conferencing. Prior to the start of the scenario, a pre-briefing session was provided. The student's performance during the simulation was recorded with video. Each simulation lasted around 30 minutes. Following the simulation, a debriefing session was held with the student, and feedback was provided. Scales were used to assess the implementation of the practices.
Study: NCT04685941

Intervention type: DRUG
Group type: OTHER
Intervention: Drug-mediated hyperemia
Description: Intracoronary bolus of at least 200 mcg of nitroprussiate or 500 mcg of intracoronary adenosine during 2 minutes. Operators are allowed to combine both drugs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flow-mediated hyperemia
Description: Intracoronary saline infusion at 20 ml/min via dedicated microcatheter (RayFlow; Hexacath, France) during two minutes.
Study: NCT03750825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIDA Standard Research E-cigarette (SREC)
Description: Smokers will switch to NIDA Standard Research E-cigarette (SREC).
Study: NCT06520228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active video games
Description: The experiment was divided into two groups. One experimental group, one control group. The experimental group received an active video game intervention for 12 weeks, 40 minutes twice a week. The control group underwent 12 weeks of traditional physical activity, 40 minutes twice a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional sports games
Description: The experiment was divided into two groups. One experimental group, one control group. The experimental group received an active video game intervention for 12 weeks, 40 minutes twice a week. The control group underwent 12 weeks of traditional physical activity, 40 minutes twice a week.
Study: NCT05829382

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DailyColors™
Description: Capsule containing active ingredient administred daily by the participant during the trial period

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule containing placebo administered daily by the participant during the trial period
Study: NCT05740059

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adjusted Transfusion
Description: Patients assigned to the SvO2 group will be transfused if Hb concentration is lower than 9 g/dL and central SvO2 ≤ 65%. Transfusion will be repeated whenever Hb concentration is lower than 9 g/dL and central SvO2 ≤ 65% during surgery and in the ICU (until day 5). Central SvO2 will be measured on a blood sample obtained from the distal lumen of the central venous catheter. Oximetry will be used for measurement with a point-of-care of gas analysis.
Study: NCT06295575

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotics containing Bifidobacterium infantis and Lactobacillus
Description: Patients were provided with probiotics containing Bifidobacterium infantis and Lactobacillus. This intervention was started the day after patients' administration and lasted until the day before discharge.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebos containing lactose
Description: Patients received lactose as placebo.This intervention was started the day after patients' administration and lasted until the day before discharge.
Study: NCT05502068

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D 25 (OH) 12000 IU in the form of a sublingual sprayable microemulsion
Description: This is a prospective, randomized, double blind, and controlled clinical study to investigate the impact of the high dose vitamin D supplementation on laboratory markers of systemic inflammation such as CRP, ferritin and IL-6 in hospitalized patients with COVID-19. Patients included in the study will be randomized into two groups and receive a placebo (as a control group) or cholecalciferol administered sublingually for 5 day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D 25 (OH) 12000 IU in the form of a sublingual sprayable microemulsion
Description: This is a prospective, randomized, double blind, and controlled clinical study to investigate the impact of the high dose vitamin D supplementation on laboratory markers of systemic inflammation such as CRP, ferritin and IL-6 in hospitalized patients with COVID-19. Patients included in the study will be randomized into two groups and receive a placebo (as a control group) or cholecalciferol administered sublingually for 5 day
Study: NCT05618353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 0.6 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT05921877

Intervention type: DIAGNOSTIC_TEST
Intervention: venous sampling
Description: venous sampling

Intervention type: DIAGNOSTIC_TEST
Intervention: venous sampling
Description: venous sampling
Study: NCT06163105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meibomian gland expression (MGX)
Description: The MGX procedure has a standardized protocol in lid spa at Chula's Refractive Surgery Center every 2 weeks (totally 6 sessions). During the study, all MGX procedures will be conducted by the same nurse following these steps:~1. Topical anesthesia by Tetracaine 0.5%~2. Clean the eyelids by gauzes with commercial available foam~3. Warm the eyelids by Blephasteam machine for 10 minutes~4. Instill Tetracaine 0.5% again~5. Use Mastrota paddle and Q-tip to squeeze the gland~6. Clean the lid margin by commercial available foam~7. Use Moxifloxacin 0.5% eyedrop
Study: NCT05319691

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: The trial will be 24 weeks long and divided into two distinct parts: an initial 12-week Treatment Phase during which, yoga participants will receive a reproducible standardized weekly yoga intervention delivered virtually with additional resources for home practice, followed by a 12-week Follow-up Phase.
Study: NCT04272736

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low calorie protein substitute
Description: The evaluated dietary supplement is a lower calorie amino acid based liquid protein substitute designed for patients with PKU.
Study: NCT06404398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OMNICHROMA, Ceram. x spectra
Description: Each patient had two types of veneers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OMNICHROMA, Ceram. x spectra
Description: Each patient had two types of veneers.
Study: NCT06087848

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)
Description: 100 x 106 allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min
Study: NCT04847635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pascal Synthesis 577 sub-threshold laser (Topcon Corporation, Tokyo, Japan)
Description: The subthreshold laser treatment will be performed using subthreshold laser Pascal Synthesis 577 on a customized macular area.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Pascal Synthesis 577 sham (Topcon Corporation, Tokyo, Japan)
Description: The laser treatment will be performed without any power (only the light beam) using subthreshold laser Pascal Synthesis 577 on a customized macular area.
Study: NCT06031246

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective Lymph Node Dissection
Description: For patients with NSCLC with CTR\>0.5 located in the apical segment, the inferior mediastinal lymph node was not need to dissected
Study: NCT05601531

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Tooth Root
Description: An autologous Tooth Root is made from one's own tooth root and covered in an extraction socket where bone graft is placed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Tooth Root
Description: An autologous Tooth Root is made from one's own tooth root and covered in an extraction socket where bone graft is placed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit.D3
Description: Local administration of Vit.D3, through the effect of Vit.D3 to explore whether it can help to accelerate the healing of tooth extraction cavity and the clinical effectiveness of bone regeneration.
Study: NCT06286592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT values video
Description: Details of the specific intervention will be selected in collaboration with the Community Advisory Board.~Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT values video
Description: Details of the specific intervention will be selected in collaboration with the Community Advisory Board.~Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board.
Study: NCT05240729

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular brachial plexus block
Description: Using ultrasound in 3different techniques of infraclavicular brachial plexus block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular brachial plexus block
Description: Using ultrasound in 3different techniques of infraclavicular brachial plexus block
Study: NCT05601531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone graft
Description: Selecting bone materials for alveolar ridge preservation according to treatment needs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone graft
Description: Selecting bone materials for alveolar ridge preservation according to treatment needs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone graft
Description: Selecting bone materials for alveolar ridge preservation according to treatment needs
Study: NCT05491473

Intervention type: DEVICE
Intervention: Closed incisional negative pressure wound therapy (iNPWT) system
Description: The closed incisional negative pressure wound therapy (iNPWT) system (PREVENA Incision Management System, KCI, an Acelity company, San Antonio, Texas, USA)
Study: NCT04833023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haldol 2mg/ml oral solution
Description: Starting dose: 1mg~Maximum Dose within 24 hours: 6mg~Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Haloperidol has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine Actavis 5mg orodispersible tablet
Description: Starting dose: 2.5mg~Maximum Dose within 24 hours: 15mg~Doses can be escalated every 2 hourly to the maximum doses allowed within 24 hours. If maximum dose of Olanzapine has been reached for the day (within 24 hours), rescue dose of Midazolam 2mg can be used (2mg Q2H PRN).